• Jesús Aibar, Mario Martínez-Florensa, Pedro Castro, Esther Carrasco, Cristina Escoda-Ferran, Sara Fernández, Montserrat Butjosa, Cristina Hernández, Mariano Rinaudo, Francisco Lozano, and Josep Maria Nicolás.
• Medical Intensive Care Unit, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. Electronic address: jaibar@clinic.ub.es.
• J Crit Care. 2015 May 9.

PurposeSoluble forms of CD5 and CD6 lymphocyte surface receptors (sCD5 and sCD6) are molecules that seem to prevent experimental sepsis when exogenously administered. The aim of this study was to assess sCD5 and sCD6 levels in patients with septic syndromes.Materials And MethodsThe study population consisted of 218 patients admitted to the medical intensive care unit (ICU) presenting either septic syndromes or noninfectious systemic inflammatory response syndrome at admission or within the first 48 hours. The sCD5 and sCD6 levels were analyzed by sandwich enzyme-linked immunosorbent assay.ResultsAlmost 50% of the patients had undetectable levels of sCD5 or sCD6, with no differences in clinical or biological variables with detectable patients. There was a correlation between the delta Sequential Organ Failure Assessment score and both sCD6 and sCD5 levels in all groups. Patients with sCD5 or sCD6 levels greater than 1500 ng/mL presented a higher in-ICU mortality (P < .05). Logistic regression analysis showed that increased sCD6 levels were associated with an increased risk of in-ICU mortality.ConclusionsLevels of sCD5 and sCD6 in critically ill patients with systemic inflammatory response syndrome present a high variation and an elevated proportion of undetectability. Levels of sCD6 are associated with an increased risk of mortality in these patients.Copyright © 2015. Published by Elsevier Inc.

2 keywords...

hide…